Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.72 | N/A | -7.46% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.72 | N/A | -7.46% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current performance but remains focused on future developments. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term goals despite current setbacks.
The earnings report indicates that Day One Biopharma is still facing challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 3.32%, likely due to investor concerns about profitability and the lack of revenue data. Without guidance, investors may remain uncertain about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HERSHEY CO
May 3, 2024